Objective:To translate the best evidence of cerebrospinal fluid external drainage management into clinical practice, so as to standardize the behavior of nurses, improve the qualified rate of cerebrospinal fluid external drainage management, and improve the quality of nursing.Methods:Follow the JBI′s Practical Application of Clinical Evidence System and Getting Research into Practice audit, the research team selected the best evidences about five dimensions, and formulated 13 evaluation criteria. A 40-case baseline audit in a Neurosurgical ward to identify problems in implementation of this evidences were performed. After that they provided training courses and strategies to get these evidences into practice, and conducted a 40-case post-implementation audit in the same ward.Results:The compliance rates of all the 13 criteria were increased except No.11 ( χ2 values were 8.889-34.290, P<0.01). The qualified rate of total amount control of cerebrospinal fluid drainage increased from 57.5% (23/40) to 100.0% (40/40), the qualified rate of drainage speed control increased from 40.0% (16/40) to 100.0% (40/40), and the qualified rate of health education increased from 42.5% (17/40) to 90.0% (36/40), with statistical significance ( χ2 values were 21.590, 34.290, 20.180, P < 0.01). Conclusions:Put the best available evidence regarding cerebrospinal fluid external drainage into practice canpromotes evidence-based nursing practice, standardized nurses′ behaviors, realized continuous improvement of nursing quality, and can reduce the risk of complications and ensure patient′s safety.

Objective To study the inhibition effect of non custodial terpenes-3β-alcohol to experimentally in-duced autoimmune encephalomyelitis in guinea pigs. Methods Different doses (25 mg/kg, 50 mg/kg and 100 mg/kg) of non custodial terpenes-3β-alcohol were given to the experimentally induced autoimmune encephalomyelitis model of guinea pigs by gavage for 8 weeks. Plasma levels of CD4+/CD8+, IL-1, IL-2, IL-6, IL-10, neuropeptide Y (NPY), beta endorphin (β-EP) , transforming growth factor-β(TGF-β), matrix metalloproteinase (MMP-2), nitric oxide synthase (NOS) and leuko-cyte differentiation antigen CD3 were assessed. The brain neuron morphology changes was observed under light microscopy while its ultrastructure changes was observed under electron microscope. NOS expression in neurons was observed through immunofluoresce technology. Results Non custodialterpenes-3β-alcohol inhibited the increase of plasma CD4+/CD8+, IL-1, IL-2, IL-6, IL-10, MMP-2, CD3 and NPY while decrease of plasmaβ-EP, brain TGF-β. It also increase NOS expres-sion in neuronal cytoplasm and maintained neuron morphology. Conclusion Non custodial terpenes-3β-alcohol inhibit-ed the experimental autoimmune encephalomyelitis in guinea pig.

The function theory of an anesthesia vaporizer was studied and the geometry configuration was measured in this study. The internal gas flow and mixing process in the anesthesia vaporizer were simulated using CFD method. Applying tracking in turbulent flow to stochastic particle, for the droplet of anesthesia drug, the moving track of droplet was traced. Based on the results, the internal gas flow variation, the concentration distribution of anesthesia drug volatilization process and mixing process with gas were ascertained. Numerical simulation results showed that, the diluted gas velocity reduction of internal flow in the anesthesia vaporizer was higher. Because of the anesthesia vaporizer geometry, the mixing process between anesthesia drug vapor and diluting gas was not homogeneous. This also influenced the stability and accuracy of anesthesia drug concentration. The optimization precept of anesthesia vaporizer is ascertained.
Anesthesia, Inhalation ; instrumentation ; Computer Simulation ; Humans ; Imaging, Three-Dimensional ; Nebulizers and Vaporizers ; standards ; Numerical Analysis, Computer-Assisted

Antibodies, Monoclonal, Murine-Derived ; adverse effects ; Antineoplastic Agents ; adverse effects ; Humans ; Lung Diseases, Interstitial ; chemically induced ; Rituximab ; Waldenstrom Macroglobulinemia ; drug therapy